EyePoint (EYPT) Short term Debt (2022 - 2023)
EyePoint (EYPT) posted Short term Debt of $5.3 million for Q1 2023, down 49.45% sequentially from $10.5 million in Q4 2022, and down 49.45% YoY from $10.5 million in Q1 2022.
Powered by 
Analysis
EyePoint (EYPT) Short term Debt (2022 - 2023) Analysis & Trends
EyePoint has reported Short term Debt for 2 years, with the latest figure at $5.3 million in Q1 2023.
- Quarterly Short term Debt fell 49.45% year-over-year to $5.3 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $5.3 million (down 49.45% YoY) and the FY2022 annual result came in at $10.5 million, changed N/A from the prior year.
- Short term Debt fell to $5.3 million in Q1 2023 per EYPT's latest filing, from $10.5 million in the prior quarter.
- Over five years, Short term Debt peaked at $10.5 million in Q1 2022 and troughed at $5.3 million in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 5.30 Mn |
| Dec 31, 2022 | 10.48 Mn |
| Sep 30, 2022 | 10.48 Mn |
| Jun 30, 2022 | 10.48 Mn |
| Mar 31, 2022 | 10.48 Mn |